Research progress in drug therapy for NSCLC with rare driver gene mutation

Abstract

After discovering the molecular changes leading to cancer occurrence and progression, the revolutionary changes have occurred in the treatment of non-small cell lung cancer (NSCLC) . The targeted therapy has become the first-line treatment for the advanced NSCLC patients with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) fusion gene. With the rapid development of targeted drugs, the clinical studies on uncommon mutations or fusions of ROS1, MET, RET, HER2 and BRAF V600E in NSCLC are progressing rapidly, providing more options and opportunities for treatment in the patients with NSCLC.

Keywords

• non-small cell lung cancer
• driver gene
• rare
• molecular targeted therapy
• epidermal growth factor receptor
• c-ros proto oncogene 1
• mesenchymal epithelial transfer factor
• proto oncogenes
• human epidermal growth factor receptor 2
• b-raf oncoprotei